Zymeworks (ZYME) Stock Price, News & Analysis

Company Overview

Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability. Complementing this is the Torque™ antibody–drug conjugate (ADC) platform, which empowers precise conjugation of cytotoxic payloads to antibodies for targeted cancer therapy. The company also leverages its Engine™ protein engineering and Armory™ discovery platforms to optimize binding affinity and multispecific formats, as well as to streamline the identification of novel therapeutic candidates.

Zymeworks’ clinical pipeline features multiple product candidates, including ZW25, a biparatopic antibody targeting two distinct domains of the human epidermal growth factor receptor 2 (HER2) for treatment of solid tumors, and ZW49, an ADC derived from ZW25 equipped with a cytotoxic payload. Another notable candidate is zenocutuzumab (ZW25-ADC), designed to target neuregulin 1 (NRG1) fusion-driven cancers. These programs underscore the company’s strategic focus on hard-to-treat oncology indications and its commitment to advancing therapies through clinical development in collaboration with global partners.

Founded in 2003 and headquartered in Vancouver, British Columbia, Zymeworks operates research and development facilities in both Canada and the United States. Under the leadership of President and Chief Executive Officer Andrew Lo, Ph.D., the company maintains strategic alliances with pharmaceutical partners and academic institutions worldwide. Zymeworks continues to expand its geographic reach and scientific collaborations as it pursues regulatory submissions and potential commercialization of its innovative biotherapeutic candidates.

Key Stats

• Today's Range: $24.70 to $26.36
• 50-Day Range: $22.49 to $28.56
• 52-Week Range: $11.51 to $29.75
• Volume: 593,296 shs
• Average Volume: 713,959 shs
• Market Capitalization: $1.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Moderate Buy

Zymeworks Stock Analysis - MarketRank™

Zymeworks scored higher than 63% of companies evaluated by MarketBeat, and ranked 37th out of 95 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Zymeworks has a consensus price target of $37.00, representing about 46.1% upside from its current price of $25.33.

Amount of Analyst Coverage

Zymeworks has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Zymeworks are expected to decrease in the coming year, from $1.10 to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zymeworks is -18.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zymeworks is -18.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zymeworks has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.24% of the float of Zymeworks has been sold short.

Short Interest Ratio / Days to Cover

Zymeworks has a short interest ratio ("days to cover") of 5.57.

Change versus previous month

Short interest in Zymeworks has recently decreased by 0.93%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zymeworks does not currently pay a dividend.

Dividend Growth

Zymeworks does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.02

News Sentiment

Zymeworks has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Zymeworks this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for ZYME on MarketBeat in the last 30 days.

MarketBeat Follows

28 people have added Zymeworks to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zymeworks insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.51% of the stock of Zymeworks is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZYME
• Previous Symbol: NASDAQ:ZYME
• CIK: 1937653
• Web: N/A
• Phone: (302) 274-8744
• Fax: 604-737-7077
• Employees: 460
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Zymeworks: $37.00
• High Price Target: $58.00
• Low Price Target: $22.00
• Potential Upside/Downside: +46.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 23.03
• P/E Growth: N/A
• Net Income: -$81.13 million
• Net Margins: -126.92%
• Pretax Margin: -127.94%
• Return on Equity: -37.97%
• Return on Assets: -25.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.82
• Quick Ratio: 10.82

Sales & Book Value

• Annual Sales: $105.96 million
• Price / Sales: 17.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.59 per share
• Price / Book: 7.06

Miscellaneous

• Outstanding Shares: 73,020,000
• Free Float: 48,553,000
• Market Cap: $1.85 billion
• Optionable: N/A
• Beta: 1.13